5.0666
price down icon2.81%   -0.1534
 
loading
전일 마감가:
$5.22
열려 있는:
$5.36
하루 거래량:
8.25M
Relative Volume:
0.36
시가총액:
$2.22B
수익:
$64.60M
순이익/손실:
$-377.75M
주가수익비율:
-3.2688
EPS:
-1.55
순현금흐름:
$-335.64M
1주 성능:
-0.72%
1개월 성능:
+24.35%
6개월 성능:
-29.93%
1년 성능:
-45.91%
1일 변동 폭
Value
$4.98
$5.36
1주일 범위
Value
$4.72
$5.36
52주 변동 폭
Value
$3.79
$12.36

리커젼 파마 Stock (RXRX) Company Profile

Name
명칭
Recursion Pharmaceuticals Inc
Name
전화
(385) 269-0203
Name
주소
41S RIO GRANDE STREET, SALT LAKE CITY
Name
직원
800
Name
트위터
Name
다음 수익 날짜
2024-11-06
Name
최신 SEC 제출 서류
Name
RXRX's Discussions on Twitter

RXRX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
RXRX
Recursion Pharmaceuticals Inc
5.0689 2.22B 64.60M -377.75M -335.64M -1.55
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.98 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
520.58 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.34 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
561.97 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
266.77 28.51B 3.81B -644.79M -669.77M -6.24

리커젼 파마 Stock (RXRX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2023-05-22 개시 Morgan Stanley Equal-Weight
2023-03-16 개시 Needham Buy
2022-09-16 개시 KeyBanc Capital Markets Overweight
2022-04-18 다운그레이드 BofA Securities Buy → Neutral
2022-03-04 다운그레이드 SVB Leerink Outperform → Mkt Perform
2021-09-21 개시 Berenberg Buy
2021-05-11 개시 BofA Securities Buy
2021-05-11 개시 Goldman Neutral
2021-05-11 개시 JP Morgan Neutral
2021-05-11 개시 KeyBanc Capital Markets Overweight
2021-05-11 개시 SVB Leerink Outperform
모두보기

리커젼 파마 주식(RXRX)의 최신 뉴스

pulisher
Jun 18, 2025

Recursion Pharmaceuticals stockholders elect three Class I directors - Investing.com Australia

Jun 18, 2025
pulisher
Jun 18, 2025

Recursion Pharmaceuticals stockholders elect three Class I directors By Investing.com - Investing.com India

Jun 18, 2025
pulisher
Jun 18, 2025

Recursion Pharmaceuticals Holds Annual Stockholder Meeting - TipRanks

Jun 18, 2025
pulisher
Jun 16, 2025

Expert Outlook: Recursion Pharmaceuticals Through The Eyes Of 4 Analysts - Benzinga

Jun 16, 2025
pulisher
Jun 16, 2025

Recursion Pharmaceuticals (RXRX): Morgan Stanley Adjusts Price Target | RXRX Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace

Jun 16, 2025
pulisher
Jun 16, 2025

Recursion Pharma to reduce workforce by 20% - MSN

Jun 16, 2025
pulisher
Jun 16, 2025

Why Recursion Pharmaceuticals Stock Is Plummeting Today - AOL.com

Jun 16, 2025
pulisher
Jun 16, 2025

Recursion Pharmaceuticals price target lowered to $5 by Morgan Stanley - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

Recursion Pharmaceuticals price target lowered to $5 from $8 at Morgan Stanley - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

Morgan Stanley Cuts Recursion Pharmaceuticals Price Target to $5 From $8, Maintains Equalweight Rating - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Is This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy? - MSN

Jun 16, 2025
pulisher
Jun 15, 2025

Why Recursion Pharmaceuticals RXRX Could Be the NVDA of Biotech for NASDAQ:RXRX by TopgOptions - TradingView

Jun 15, 2025
pulisher
Jun 14, 2025

Recursion to lay off 20% of workforce, narrows focus amid biotech downturn - MSN

Jun 14, 2025
pulisher
Jun 13, 2025

Recursion Q1 2025 slides: AI platform advances pipeline amid earnings miss By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Recursion Q1 2025 slides: AI platform advances pipeline amid earnings miss - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

Cautious Outlook on Recursion Pharmaceuticals Amid Strategic Restructuring and Cash Management Challenges - TipRanks

Jun 13, 2025
pulisher
Jun 11, 2025

Insmed surges on lung drug data; Recursion cuts staff - Yahoo Finance

Jun 11, 2025
pulisher
Jun 11, 2025

Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today - MSN

Jun 11, 2025
pulisher
Jun 11, 2025

Recursion: Lack Of Near-Term Catalysts Leaves The Stock Vulnerable (NASDAQ:RXRX) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 10, 2025

Recursion Pharmaceuticals (RXRX) Jumps 31% On Next-Gen AI - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion to lay off 20% of workforce amid biotech funding woes - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Why Recursion Pharmaceuticals Was Bouncing Higher on Tuesday - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

After pipeline cull, AI drug developer Recursion cuts staff by 20% - FirstWord Pharma

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Eliminating 20% of Workforce, Citing Pipeline Pruning and Capital Markets - Genetic Engineering and Biotechnology News

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Pharmaceuticals Stock Surges After Company Lays Off 20% Workforce: Retail Predicts ‘Blue Skies’ Ahead - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Pharmaceuticals Stock Is Up 10% Today: What's Happening? - Benzinga

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Downsizes by 20% To Boost Cash Position - BioSpace

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion lays off 20% of staff in wake of pipeline cutbacks - Fierce Biotech

Jun 10, 2025
pulisher
Jun 10, 2025

Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Pharmaceuticals: Recent Readouts Disappointing, Future Readouts Risky (RXRX) - Seeking Alpha

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Cuts 20% of Workforce, Extends Cash Runway to Late 2027 - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Pharma to reduce workforce by 20% (RXRX:NASDAQ) - Seeking Alpha

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Pharmaceuticals Stock (RXRX): AI Breakthrough for Drug Development - Value The Markets

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Pharmaceuticals (RXRX) Implements Workforce and Operat - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Pharmaceuticals Announces Workforce Reduction Strategy - TipRanks

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Pharmaceuticals announces 20% workforce reduction - TipRanks

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Pharmaceuticals Announces Personnel And Infrastructure ReductionSEC Filing - marketscreener.com

Jun 10, 2025
pulisher
Jun 08, 2025

15 Stocks That Stole The Show Last Week - Insider Monkey

Jun 08, 2025
pulisher
Jun 07, 2025

Recursion rises on launch of Boltz-2 in partnership with MIT - MSN

Jun 07, 2025
pulisher
Jun 07, 2025

Why Recursion Pharmaceuticals (RXRX) Soared On Friday - Insider Monkey

Jun 07, 2025
pulisher
Jun 06, 2025

10 Stocks Are Dominating Like Wall Street Titans - Insider Monkey

Jun 06, 2025
pulisher
Jun 06, 2025

Recursion Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:RXRX - Benzinga

Jun 06, 2025
pulisher
Jun 06, 2025

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas - mx.advfn.com

Jun 06, 2025
pulisher
Jun 06, 2025

Recursion Pharmaceuticals Stock Surges On Breakthrough AI Model Launch With MIT - Benzinga

Jun 06, 2025
pulisher
Jun 06, 2025

Recursion Pharmaceuticals shares surge on AI model release By Investing.com - Investing.com South Africa

Jun 06, 2025
pulisher
Jun 06, 2025

Recursion Pharmaceuticals shares surge on AI model release - Investing.com

Jun 06, 2025
pulisher
Jun 06, 2025

Recursion Pharmaceuticals call volume above normal and directionally bullish - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

Recursion Pharmaceuticals (RXRX) Sees Surge in Bullish Options Activity | RXRX Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Recursion (RXRX) Shares Jump on New Biomolecular Model Launch - GuruFocus

Jun 06, 2025

리커젼 파마 (RXRX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.44
price down icon 1.37%
$35.78
price down icon 1.08%
$20.60
price down icon 1.45%
$104.96
price down icon 0.97%
$103.92
price down icon 1.26%
biotechnology ONC
$266.74
price up icon 0.06%
자본화:     |  볼륨(24시간):